Introduction: In this study, we aimed to analyze craniofacial morphology by assessing the skeletal cephalometric profiles of HIV-positive patients receiving antiretroviral therapy. Methods: For this study, 21 HIVpositive patients aged between 6 and 17 years (study group) were selected and compared with 21 normoreactive patients (control group), paired by sex and age. The patients were also divided into 3 age ranges (6-8, 9-12, and 13-17 years) considering the pubertal growth spurt as the central event. Eighteen (linear and angular) measurements were traced on teleradiographs by using 2 methodologies. The mean values of each measurement were compared between the study and control groups by age range. Results: The majority of the measurements checked in the HIV-positive children and adolescents for the 13-to-17 year age range were diminished, but not enough to generate a statistically significant difference in craniofacial growth. Statistically significant differences (P \0.05) were found only in the inclination of the palatal plane (6-8 years) and the position of the maxilla in the anteroposterior direction (13-17 years). Conclusions: These results led us to conclude that some cephalometric measurements of HIV-positive children and adolescents may be similar to those of normoreactive subjects. (Am J Orthod Dentofacial Orthop 2018;153:26-35) 
W
ith the implementation of highly active antiretroviral therapy (HAART) in the 1990s, patients with human immunodeficiency virus (HIV1) experienced a significant increase in their quality and expectation of life. But in a short while, the adverse effects of the combination of antiretroviral drugs began to be identified through the compromised physiologic functions in several systems and organs. [1] [2] [3] [4] Although most reports on the adverse effects of the medication were related to adults, HIV1 children have also been affected. These changes identified in the pediatric population include mitochondrial toxicity, 5 lipodystrophy, 6 dyslipidemias and insulin resistance, 7 hypertension, 8 liver dysfunction, 9 cardiac dysfunction, 10 increased risk for cardiovascular 11 and cerebrovascular 12 diseases, renal toxicity, and low bone mineral density. 12 Perinatally, HIV infected children also showed a growth deficit resulting in reduced height. 13 Stagi et al 14 stated that "the losses in stature accumulated throughout the total period of childhood and adolescence may contribute to the reduced final height" of perinatally HIV infected patients.
Because these children had reduced bone mineral density, the use of HAART appeared to increase the complications as a result of the low bone mineral density. 13 Since this population is at a stage of growth and development, it is natural that these complications are potentially more severe than they are in adults.
immunodepression. [16] [17] [18] [19] With the increased survival and immunologic reconstitution making the opportunist manifestations unfeasible, now the questions relative to the oral health of these patients are focused on their conventional dental management under the deleterious effects caused on various organs and systems by both the medication and the virus itself. 20 Clinical studies have been conducted to verify the feasibility of dental treatments that act on mineralized tissues, since these may be a new source of concern for dentists treating patients undergoing HAART. 21 Trigueiro et al 22 pointed out a change in the development of mineralized tissues in the oral region of HIV-infected children; they found a delayed dental age compared with chronologic age, including a positive association between antiretroviral therapy and delay in the chronology of tooth mineralization.
Thus, it is possible that changes may be verified not only in teeth, but also in the craniofacial growth pattern of HIV1 children and adolescents undergoing antiretroviral therapy.
Several studies have demonstrated the capacity of medications and chronic systemic diseases to lead to changes in craniofacial growth and development. [23] [24] [25] [26] [27] [28] [29] [30] [31] However, no such studies of HIV/AIDS patients were found; therefore, there is no way to estimate whether the disease or its treatment can influence craniofacial growth.
Recent studies have pointed out that there are few studies about children and adolescents with HIV, and particularly about the adverse effects of HAART on this population. 32, 33 At the 7th World Workshop on Oral health and Disease in AIDS, the researchers identified the need for better knowledge about the orofacial health problems of HIV1 children. 33 In agreement with the most recent concerns raised in this area of research, the aims of this study were to analyze the craniofacial morphology by evaluating the skeletal cephalometric profile of HIV1 patients, all infected by vertical transmission and submitted to antiretroviral therapy and to compare them with normoreactive patients. We justified the use of a pilot study to verify the need for longitudinal research.
MATERIAL AND METHODS
A case-control study was conducted with a convenience sample of consecutive patients seropositive for HIV and normoreactive patients who attended a dental office in São Paulo, Brazil, for orthodontic treatment during 12 months. The protocol of this study was approved by the local research ethics committee.
The study group was composed of 21 patients of both sexes aged between 6 and 17 years. All patients were vertically HIV infected, with positive serology confirmed in at least 2 different tests, and had been undergoing antiretroviral therapy since they were born.
The control group included 21 normoreactive patients matched by sex and age with the study patients, all attending a private dental office in São Paulo, Brazil, for orthodontic treatment. Anamnesis and clinical examinations were the sources of information for verifying the absence of chronic systemic diseases and prolonged use of drugs among the patients.
The patients excluded from the study were those undergoing any long-term systemic therapy for chronic diseases (except AIDS in the study group), who had received radiotherapy, chemotherapy, or any previous orthodontic or orthopedic treatment, and who had any neuropsychomotor impairment.
Orthodontic documentation for diagnosis included facial photographs (2 front views, 1 profile), panoramic radiograph, lateral teleradiograph, and study casts.
For this research, we used teleradiographs only, on which cephalometric points of the hard profile were identified and used for measuring the craniofacial morphology. In total, 14 points and 18 (linear and angular) measurements were used, all based on the studies by El-Bialy (Table I) .
et al, 24 Thordarson et al, 34 Niles et al, 31 Fjeld et al, 28 Sadeghianrizi et al, 26 Orup et al, 25 Al-Thomali and ElBialy, 30 Amini et al, 27 and Gjorup et al 29 (Fig) . To minimize measurement errors, the cephalometric points and measurements were traced with 2 methodologies.
In the first (semiautomated) methodology for tracing the cephalograms, a dental radiology specialist used a Compaq Presario microcomputer (1.7 Ghz, 768 Mb RAM, HD of 30 Gb, Windows XP SP3; Pentium 4; Hewlett Packard, Palo Alto, Ca) and Radiocef Studio 2 software (RadioMemory, Belo Horizonte, Brazil). The cephalometric points were manually marked, and the software traced the lines and angles, including pertinent measurements.
In the second (manual) methodology for each radiograph, a specialist in orthodontics used a transparent acetate sheet (Ultraphan; 3M Unitek, Monrovia, Calif) measuring 8 3 10 in and 0.003 in thick as well as a propelling pencil (Pentel do Brasil, Diadema, Brazil) with 0.5-mm thick graphite to trace the points, with the measurements performed manually.
All measurements were entered into a spreadsheet (Microsoft Office Excel 2007; Microsoft, Redmond, Wash) to obtain the arithmetic mean values of each angle and linear measurement found by the semiautomated and manual methodologies. The data obtained for the study and control groups were compared.
The patients were also subdivided according to the pubertal growth spurt, and the subgroups were compared. We considered that the pubertal growth spurt in girls occurred from 8 years of age, 35 reaching its peak at 12 years, 36 whereas in boys it occurred from 9 years 35 and reached its peak at 14 years. 36 Thus, the time interval between 9 and 12 years was chosen as the main growth spurt period for both sexes. Consequently, 2 other age ranges were defined: before the growth spurt (6-8 years old) and after the growth spurt (13-17 years old).
The data were analyzed by using the Epiinfo 7 software, and the Bartlett test was performed to verify the homogeneity of variances (P .0.05). For variables without a normal distribution, the Wilcoxon test was applied. The significance level was set at 0.05 or 5%.
To determine the reliability of agreement between the 2 measurement methodologies, the intraclass correlation coefficient was used for statistical analysis.
RESULTS
Twenty-one subjects were evaluated in the study group, of whom 10 were girls and 11 were boys, all aged between 6 and 17 years (mean age, 11.7 years). All had been diagnosed with HIV at birth and treated with antiretroviral therapy since the first year of life. At the time of clinical evaluation, the mean count of CD41 T lymphocytes in the study group was 752 cells per cubic millimeter (minimum, 180 cells/mm 3 ; maximum, 1727 cells/mm 3 ). Only 2 patients had no undetected viral load (5418 and 41,395 copies). These patients were also the only ones to have CD41 T lymphocyte counts out of the normal range (273 and . Four used front-line drugs composed of 2 nucleoside reverse transcriptase inhibitors and 1 nonnucleoside reverse transcriptase inhibitor. Twelve patients used second-line combinations (2 nucleoside reverse transcriptase inhibitors plus 1 protease inhibitor with ritonavir booster). Two patients used 2 nucleoside reverse transcriptase inhibitors plus 1 protease inhibitor. Three patients used the following combinations: 2 nucleoside reverse transcriptase inhibitors plus 1 protease inhibitor with ritonavir booster plus 1 protease inhibitor; 2 nucleoside reverse transcriptase inhibitors plus 1 protease inhibitor plus 1 integrase inhibitor; 3 nucleoside reverse transcriptase inhibitors plus 1 protease inhibitor with ritonavir booster.
With regard to the methodologies used for evaluating the cephalometric measurements, we observed that the methods agreed with each other for almost all variables, with high intraclass correlation coefficient values (Table II) .
The exceptions were the variables Co-A, SN.ANSPNS, and SNB, which had agreement of 60%. Nevertheless, we affirmed that the agreement was positive for SN.ANSPNS and SNB, since the P values were statistically significant (less than 0.05). As for the Co-A, the P value was marginally out of the significance range (Table II) .
The cephalometric measurements of the study and control groups were compared according to the different age groups, as listed in Tables III, IV , and V.
In the 6-to-8 year age group, when considering the mean values, the positions of the maxilla and the mandible in the study group were slightly retruded in relation to the base of the skull compared with the control group. In addition, the growth pattern in the study group was more horizontal, and the effective size of the bone bases was slightly greater than in the control group. However, the differences were not statistically significant, except for the palatal plane inclination, which differed significantly between the 2 groups (Table III) .
With regard to the mean values in the 9-to-12 year age group, the maxilla was slightly retruded, and the mandible was protruded in the study group in relation to the base of the skull compared with the control group. Also, the former had a smaller effective maxillary size and a larger effective mandibular size than the latter. In this age group, growth patterns were similar in both groups. None of the measurements (values related to maxillary and mandibular positions in the anteroposterior direction, growth pattern, and effective linear measurements) in this age group showed statistically significant differences between the study and control groups (Table IV) .
With regard to the mean values in the 9-to-12 year age group, the position of the maxilla in the study group was slightly retruded, and the mandible was protruded in relation to the base of the skull compared with the control group. Although the former had an effective maxilla size smaller than that of the latter, the effective mandibular size was similar between the 2 groups. The growth pattern was slightly more horizontal in the study group than in the control group. The only statistically significant difference was the position of the maxilla in the anteroposterior direction (SNA) ( Table V) .
DISCUSSION
HAART has undoubtedly brought benefits to HIV1 patients since this epidemic began, increasing their life expectancy and improving their systemic condition, allowing them to have access to dental treatments that previously appeared to be contraindicated or even inaccessible, especially to this population. 21 Children and adolescents seropositive for HIV now attend the dental office and demand full treatment for their oraldental health. In this context, it seems adequate to verify whether this population has craniofacial changes that may be predicted so that they can be preventively and satisfactorily managed. The aim of this study was to identify these changes.
Studies evaluating the growth and development of the face have identified that, up to 5 years of age, rapid growth velocity, well-developed craniometric dimensions, and particularly significant increases in the height and width of the jaw are observed. But the greatest gain in growth occurs after 5 years of age, with continuous and gradual increases in jaw length and facial height, width, and depth, until the craniofacial dimensions reach maturity during adolescence, between 13 and 15 years of age. 37 Moreover, Katsadouris and Halazonetis 38 claimed that "the initial shape of the craniofacial complex co-varied weakly with the direction of shape change during growth." Because of the limitations inherent in a cross-sectional study, the differences that could be found in the different age groups in our study suggest continuous craniofacial growth, with the whole face growing vertically and horizontally in both groups.
In these results, we found that 2 measurements had statistically significant differences: the angle between the palatal plane and the base of the skull (SN.ANSPNS) and the angle demonstrating the position of the maxilla in the anteroposterior direction (in relation to the base of the skull), represented by SNA.
In the 6-to-8 year age range, the SN.ANSPNS values showed that the rotation of the maxilla (palatal plane) was greater in the HIV1 patients, but these values diminished in the subsequent age groups, accompanying the values of the normoreactive patients. In 1953, Brodie 39 studied the growth of the maxilla and observed that both line SN and the palatal plane maintained constant inclinations, but when there were changes, ANS tended to become displaced inferiorly to PNS. However, no significant changes in the conclusion of growth were observed; this also occurred in the patients in our study group.
On the other hand, the angle SNA was shown to be significantly reduced in the 13-to-17 year age group. The reduction in this measurement was interpreted as retrusion of the maxillary bone. 40 Although our study was not longitudinal, there were 3 possible interpretations for this craniofacial change. The first was that this change may be a consequence of the respiratory pattern of HIV1 patients, which is compromised by successive airway infections during the period of growth. SNA may be reduced in those with compromised respiratory function of the upper airway, as in mouth-breathing patients. 41 Researchers who have evaluated the frequency of respiratory changes in HIV1 children have found that they were more likely to have respiratory difficulties. 42 Zastrow et al 43 reported no difference in the type of respiration (nose or mouth) between HIV1 and normoreactive children, but found a lower nasal flow rate in children seropositive for HIV.
It was also possible to infer the participation of both HIV and HAART in a supposed growth deficit.
The HIV infection itself, associated or not with states of immune activation and inflammatory processes, may change osteoclastogenesis by increasing the rate of apoptosis of primary osteoblasts, reducing calcium deposition and alkaline phosphatase activity, diminishing specific bone proteins and compromising the differentiation of mesenchymal cells into osteoblasts. 43 Moreover, the long-term use of HAART may be responsible for systemic alterations that affect the growth of these children. 5, 7, 12, 13 On the other hand, HAART emerged as a solution to the deleterious effects caused by the virus by diminishing the circulating viral load. Parallel to this, the immunologic reconstitution induced by the use of antiretroviral agents, expressed by the increase in CD41 T lymphocytes, has allowed patients to be clinically more stable, with reductions in opportunist infections that could cause malnutrition. Since efficient ingestion and metabolization of nutrients are important factors for maintaining bone mineral health, it is plausible that some studies have identified increases in the rates of growth and development in HIV1 children receiving HAART. 44 Nevertheless, although the gains in weight and height among HIV1 children undergoing HAART are important, these gains are less than the weight and height gains of normoreactive children. 45, 46 In this study, the other linear and angular values of HIV1 children had no statistically significant differences compared with the control group, However, it was possible to identify a trend toward reduction in the linear measurements of the maxilla, mandible, and base of the skull in the study patients between 13 and 17 years old. In this age group, 14 angular and linear measurements in the study patients were lower than those of the controls. This difference was observed only in 5 measurements in the 6-to-8 year age group and in 7 measurements in the 9-to-12 year age group. We believe that these findings may be a basis for a longitudinal study with these patients. Nevertheless, this study was cross-sectional and did not establish a cause-andeffect relationship; this may be a limitation of our study.
Another limitation and possible confounding factor of the study was that only teleradiographs of children who were referred for orthodontic treatment were included and consequently they had some degree of deviation from normality (in both groups). An ideal study design would include all children, irrespective of the need for orthodontic treatment. But on this point, ethical questions are raised as a result of submitting children and adolescents to ionizing radiation not only during their growth period, but also at various times throughout life, only to observe possible changes in their craniofacial growth. 47, 48 It was not possible to state that either HIV or HAART alone is responsible for a possible developmental delay, or to evaluate HIV1 patients with and without the use of HAART separately, since in Brazil virtually all HIV1 children who are under medical follow-up are also receiving antiretroviral treatment.
Also, although 18 comparisons per group were made, only 2 measurements had statistically significant differences with a marginally significant P value. Since no overall important differences were found between the 2 groups in our study, we hypothesized that the beneficial effects of antiretroviral therapy overcame the adverse effects.
CONCLUSIONS
The majority of the measurements in HIV1 children and adolescents were not sufficiently different from the control group to generate a statistically significant difference in craniofacial growth. Further studies should be conducted to verify the consistency of this finding.
